Risk-Adapted Letermovir Prophylaxis Based on a Scoring System Predicting a Higher Burden of Cytomegalovirus Exposure After Allogeneic Hematopoietic Cell Transplantation

Authors:

Abstract
No abstract available
Funding Information
  • Merck
  • Takeda Pharmaceutical Company

This publication has 40 references indexed in Scilit: